INCREASED ABSORPTION OF POLYSUCROSE, A MARKER OF INTESTINAL PARACELLULAR PERMEABILITY, IN CROHNS-DISEASE

被引:7
作者
BLOMQUIST, L
OMAN, H
HENRIKSSON, K
JOHANSSON, SGO
机构
[1] Karolinska Hospital, Department of Internal Medicine
[2] Karolinska Hospital, Department of Clinical Immunology
[3] Karolinska Hospital, Department of Rheumatology, Stockholm
关键词
POLYSUCROSE; INTESTINAL PERMEABILITY; INTESTINAL ABSORPTION; MACROMOLECULAR SYSTEMS; CROHNS DISEASE;
D O I
10.1097/00042737-199311000-00004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To examine whether synthetic polysucrose behaves as a transcellular or paracellular marker in patients with Crohn's disease and in healthy subjects. Design: Patients with Crohn's disease (n = 23) and age- and sex-matched healthy controls (n = 22) were given an oral dose of polysucrose with a mean molecular weight of about 15 kDa, administered with a standard meal. Methods: Intestinal permeability to polysucrose was estimated as urinary excretion of the compound measured by immunoassay during 0-4, 4-8 and 8-12 h. Results: Urinary excretion values for polysucrose in the controls had a non-symmetrical frequency distribution and were not correlated to urinary volume. For the Crohn's disease group, intestinal permeability to polysucrose was significantly increased for the intervals 4-8 h and 8-12 h (P < 0.05). Permeability was more increased in small intestinal disease than in colonic disease, and more increased in active than in quiescent disease; hence, in patients with active Crohn's disease of the small intestine, intestinal permeability to polysucrose was significantly increased for all three time intervals (0-4, P < 0.05; 4-8 h, P < 0.001; 4-12 h, P < 0.01). Peak urinary excretion of polysucrose occurred later in the Crohn's disease patients than in the controls. Conclusions: Intestinal permeability to polysucrose is increased in Crohn's disease. In Crohn's disease patients and in healthy controls, polysucrose behaves as earlier described for known markers of paracellular intestinal permeability such as Cr-51-ethylenediamine tetraacetic acid (Cr-51-EDTA) and lactulose. We conclude that polysucrose, which has the advantage of being both non-radioactive and resistant to bacterial degradation, may be used as such a marker.
引用
收藏
页码:913 / 917
页数:5
相关论文
共 32 条
[1]  
Menzies I.S., Transmucosal passage of inert molecules in health and disease, Falk Symposium 36. Intestinal Absorption and Secretion, pp. 527-543, (1984)
[2]  
Bjarnason I., Peters T.J., Levi A.J., Intestinal permeability: Clinical correlates, Dig Dis, 4, pp. 83-92, (1986)
[3]  
Katz K.D., Hollander D., Intestinal mucosal permeability and rheumatological diseases, Baillère’s Clin Rheumatol, 3, pp. 271-284, (1989)
[4]  
Hollander D., The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn’s disease, Scand J Gastroenterol, 27, pp. 721-726, (1992)
[5]  
Maxton D.G., Bjarnason I., Reynolds A.P., Catt S.D., Peters T.J., Menzies I.S., Lactulose, <sup>51</sup>Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 as probe markers for assessment in vivo of human intestinal permeability, Clin Sci, 71, pp. 71-80, (1986)
[6]  
Marcial M.A., Carlson S.L., Madara J.L., Partitioning of para-cellular conductance along the ileal crypt-villous axis: A hypothesis based on structural analysis with detailed consideration of tight junction structure-function relationships, J Membr Biol, 80, pp. 59-70, (1984)
[7]  
Ukabam S.O., Cooper B.T., Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease, Dig Dis Sci, 29, pp. 809-816, (1984)
[8]  
Behrens R.H., Szaz K.F., Northrop C., Elia M., Neale G., Radionuclide tests for the assessment of intestinal permeability, Eur J Clin Invest, 17, pp. 100-105, (1987)
[9]  
Juby L.D., Rothwell J., Axon A., Lactulose/mannitol test: An ideal screen for celiac disease, Gastroenterology, 96, pp. 79-85, (1989)
[10]  
Menzies I.S., Laker M.F., Pounder R., Bull J., Heyer S., Wheeler P.G., Et al., Abnormal intestinal permeability to sugars in villous atrophy, Lancet, 2, pp. 1107-1109, (1979)